218457-67-1
中文名称
6-[4-(叔丁基)苯氧基]吡啶-3-胺
英文名称
5-AMINO-2-(4-TERT-BUTYLPHENOXY)PYRIDINE
CAS
218457-67-1
分子式
C15H18N2O
MDL 编号
MFCD00052647
分子量
242.32
MOL 文件
218457-67-1.mol
更新日期
2026/01/16 11:34:50
218457-67-1 结构式
基本信息
中文别名
6-[4-(叔丁基)苯氧基]吡啶-3-胺 英文别名
5-AMINO-2-(4-TERT-BUTYLPHENOXY)PYRIDINE6-[4-(TERT-BUTYL)PHENOXY]PYRIDIN-3-AMINE
BUTTPARK 96\12-100
所属类别
医药中间体：吡啶类化合物物理化学性质
熔点89-90
储存条件2-8°C
溶解度溶于 DMSO (>30 mg/ml)
形态固体
颜色灰白色至淡橙色
稳定性可在-20°C下的DMSO中的溶液储存长达3个月。
InChI1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3
InChIKeyWHIWGRCYMQLLAO-UHFFFAOYSA-N
SMILESNc1cnc(cc1)Oc2ccc(cc2)C(C)(C)C
安全数据
警示词警告
危险性描述H302-H315-H319-H335
防范说明P271-P261-P280
危险品标志Xi
WGK GermanyWGK 3
Hazard NoteIrritant
海关编码2933399990
存储类别11 - Combustible Solids
6-[4-(叔丁基)苯氧基]吡啶-3-胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mg | 298元 |
| 2025/12/22 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 10 mM * 1 mLin DMSO | 327元 |
| 2025/12/22 | HY-135145 | 6-[4-(叔丁基)苯氧基]吡啶-3-胺 Limantrafin | 218457-67-1 | 25 mg | 445元 |
常见问题列表
生物活性
CB-103 是一种口服活性的 Notch 转录激活复合物的抑制剂。CB-103 可在果蝇和小鼠中产生Notch功能丧失的表型，并抑制人类乳腺癌和白血病异种移植瘤的生长。靶点
| Target | Value |
|
Notch
() |
体外研究
CB-103 acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.
CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.
CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
Cell Viability Assay
| Cell Line: | RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 days, 6 days |
| Result: | Caused a significant reduction in their growth potential. |
体内研究
CB-103 inhibits NOTCH dependent cellular processes in mice.
CB-103 blocks in vivo growth of PDX models of T-ALL.
CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.
CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.
| Animal Model: | NSG mice, triple negative breast cancer mouse xenograft model |
| Dosage: | 25 mg/kg |
| Administration: | Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks |
| Result: | Inhibited growth of GSI/Mab resistant triple negative breast cancer. |